Vericel Corp Ord
$ 38.57
3.18%
11 Jun - close price
- Market Cap 1,891,056,000 USD
- Current Price $ 38.57
- High / Low $ 39.05 / 36.81
- Stock P/E 86.12
- Book Value 6.98
- EPS 0.43
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.07 %
- 52 Week High 43.57
- 52 Week Low 28.95
About
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$55.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-07-31 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-02 |
| Reported EPS | -0.12 | 0.45 | 0.1 | -0.01 | -0.23 | 0.38 | -0.02 | -0.1 | -0.08 | 0.26 | -0.05 | -0.11 |
| Estimated EPS | -0.16 | 0.3938 | -0.01 | -0.04 | -0.13 | 0.34 | -0.05 | -0.09 | -0.1 | 0.17 | -0.12 | -0.15 |
| Surprise | 0.04 | 0.0562 | 0.11 | 0.03 | -0.1 | 0.04 | 0.03 | -0.01 | 0.02 | 0.09 | 0.07 | 0.04 |
| Surprise Percentage | 25% | 14.2712% | 1100% | 75% | -76.9231% | 11.7647% | 60% | -11.1111% | 20% | 52.9412% | 58.3333% | 26.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCEL
2026-06-11 11:09:13
This article provides an overview of analyst ratings for two healthcare companies, Rezolute (RZLT) and Vericel (VCEL). Douglas Tsao from H.C. Wainwright reiterated a Buy rating for Rezolute with a $5.00 price target, while Josh Jennings from TD Cowen reiterated a Buy rating for Vericel with a $55.00 price target. Both companies maintain a Strong Buy consensus rating among analysts, with significant upside potential noted for Rezolute.
2026-06-09 12:08:49
Vericel Corporation announced it will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026. A webcast of the presentation will be available on the Investor Relations section of the Company's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care markets, marketing products like MACI, Epicel, and NexoBrid.
2026-06-04 20:09:30
Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, exercised stock options for 4,375 shares at $16.66 per share and simultaneously sold those 4,375 shares at $35.00 per share. These transactions were executed automatically under a pre-arranged Rule 10b5-1 trading plan. After the sales, Hopper directly holds 75,753 shares of Vericel common stock and retains 1,625 stock options.
2026-06-02 18:51:28
A recently filed Form 144 by Vericel Corp (VCEL) indicates a proposed sale of 4,375 shares of common stock by Fidelity Brokerage Services LLC, dated June 2, 2026, described as an "option-related sale with cash proceeds." The filing also notes a past sale by Jonathan M. Hopper of 3,472 shares on April 2, 2026, for $121,520.00. This is a procedural disclosure to notify the market of an intended resale of restricted or control stock.
2026-05-30 18:59:00
Soleus Capital Management recently bought an additional 1.785 million shares of Vericel (NASDAQ:VCEL), an estimated $63.40 million investment. Despite recent struggles in its stock price, Vericel's revenue climbed 20% year over year, with gross margins expanding and adjusted EBITDA more than doubling. The company also received FDA clearance for a Phase 3 study, indicating potential future growth.
2026-05-19 20:10:40
Vericel Corporation (VCEL) has amended its corporate bylaws to reflect its new global headquarters located at 25 Blue Sky Drive, Burlington, Massachusetts 01803. The amendment was approved by the Board of Directors and became effective on May 18, 2026. This change ensures that the company's official corporate records align with its updated principal executive office address.
